| Pharmaceutical Information |
| Drug Name |
Radium chloride ra-223 |
| Drug ID |
BADD_D01902 |
| Description |
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm. |
| Indications and Usage |
Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.
|
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB08913
|
| KEGG ID |
D10398
|
| MeSH ID |
C581106
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
50419-208 |
| UNII |
Not Available
|
| Synonyms |
radium Ra 223 dichloride | radium chloride Ra 223 | Xofigo |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
444811-40-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
